UPDATE: Dawson James Initiates Affymax at Market Outperform on Momentum
Dawson James initiated coverage on Affymax (NASDAQ: AFFY) with a Market Outperform rating and a $32 price target.
Dawson James commented, "Commercialization of new products is always tricky, especially in the current environment; however, we believe Omontys is an ideal product for the dialysis market given the new “bundled” pricing structure. … In addition, the receipt of a permanent “J code” (taking effect January 1, 2013) from the Centers for Medicare and Medicaid Services (CMS) should help lubricate reimbursement conditions and persuade any hold-outs to make the conversion from Epogen to Omontys. As sales growth momentum continues, so also should share price appreciation."
Affymax closed at $23.55 on Monday.
Latest Ratings for AFFY
|Mar 2013||McNicoll Lewis Vlak||Downgrades||Sell|
|Feb 2013||Lazard Capital Markets||Downgrades||Buy||Neutral|
|Feb 2013||McNicoll Lewis Vlak||Downgrades||Buy||Hold|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.